Postmenopausal syndrome

Pronob K Dalal, Manu Agarwal, Pronob K Dalal, Manu Agarwal

Abstract

Menopause is one of the most significant events in a woman's life and brings in a number of physiological changes that affect the life of a woman permanently. There have been a lot of speculations about the symptoms that appear before, during and after the onset of menopause. These symptoms constitute the postmenopausal syndrome; they are impairing to a great extent to the woman and management of these symptoms has become an important field of research lately. This chapter attempts to understand these symptoms, the underlying pathophysiology and the management options available.

Keywords: Hot flushes; menopausal depression; postmenopausal syndrome.

Conflict of interest statement

Conflict of Interest: None declared

References

    1. Sherwin B. Menopause: Myths and realities. Psychological aspects of women's health care. In: Stotland NL, Stewart DE, editors. The Interface Between Psychiatry and Obstetrics and Gynecology. Arlington: American Psychiatric Publishing; 2001. pp. 241–59.
    1. Spinelli MG. Depression and hormone therapy. Clin Obstet Gynecol. 2004;47:428–36.
    1. Adena MA, Gallagher HG. Cigarette smoking and the age at menopause. Ann Hum Biol. 1982;9:121–30.
    1. Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on the age at ovarian failure: Identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril. 1987;47:94–100.
    1. Soares CN, Taylor V. Effects and management of the menopausal transition in women with depression and bipolar disorder. J Clin Psychiatry. 2007;68(Suppl 9):16–21.
    1. Baram D. Physiology and symptoms of menopause. In: Steward DE, Robinson GE, editors. A Clinician's Guide to Menopause. Health Press International: Washington DC; 1997. pp. 9–28.
    1. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Fertil Steril. 2001;76:874–8.
    1. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA. 1979;242:2405–4.
    1. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065–79.
    1. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, et al. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med. 1997;157:2609–15.
    1. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol. 1999;94:330–6.
    1. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA. 1980;244:1443–5.
    1. Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol. 1990;76:573–8.
    1. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol. 1987;156:561–5.
    1. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA. 2003;289:2827–34.
    1. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578–83.
    1. Suvanto-Luukkonen E, Koivunen R, Sundström H, Bloigu R, Karjalainen E, Häivä-Mällinen L, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005;12:18–26.
    1. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet. 2000;356:2059–63.
    1. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16:495–500.
    1. Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000;152:463–73.
    1. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol. 2003;101:264–72.
    1. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: Systemic absorption and effects on the endometrium. Obstet Gynecol. 1994;84:215–8.
    1. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180:1072–9.
    1. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T, et al. Postmenopausal hormones and incontinence: The Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol. 2001;97:116–20.
    1. Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B. Study of Osteoporotic Fractures Research Group. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab. 2001;86:5700–5.
    1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
    1. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: A randomized controlled trial. JAMA. 2003;290:1042–8.
    1. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668–76.
    1. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol. 2004;104:443–51.
    1. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998;280:2077–82.
    1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–52.
    1. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–45.
    1. Soares CN. New York, Arlington, VA: American Psychiatric Publishing; 2004. Perimenopause-related Mood Disturbance: An Update on Risk Factors and Novel Treatment Strategies Available. In: Meeting Program and Abstracts. Psychopharmacology and Reproductive Transitions Symposium. American Psychiatric Association 157th Annual Meeting; May 1.6, 2004; pp. 51–61.
    1. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry. 2004;61:62–70.
    1. Maartens LW, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: A community based prospective study. Maturitas. 2002;42:195–200.
    1. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63:385–90.
    1. Steiner M, Dunn E, Born L. Hormones and mood: From menarche to menopause and beyond. J Affect Disord. 2003;74:67–83.
    1. Halbreich U. Role of estrogen in postmenopausal depression. Neurology. 1997;48:16–9.
    1. Huttner RP, Shepherd JE. Gonadal steroids, selective serotonin reuptake inhibitors, and mood disorders in women. Med Clin North Am. 2003;87:1065–76.
    1. Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am. 2003;26:581–94.
    1. Charney DA, Stewart DE. Psychiatric aspects. In: Steward DE, Robinson GE, editors. A Clinician's Guide to Menopause. Health Press International: Washington DC; 1997. pp. 129–44.
    1. Payne JL. The role of estrogen in mood disorders in women. Int Rev Psychiatry. 2003;15:280–90.
    1. Bromberger JT, Assmann SF, Avis NE, Schocken M, Kravitz HM, Cordal A. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol. 2003;158:347–56.
    1. Dennerstein L, Lehert P, Burger H, Dudley E. Mood and the menopausal transition. J Nerv Ment Dis. 1999;187:685–91.
    1. Rasgon NL, Dunkin J, Fairbanks L, Altshuler LL, Troung C, Elman S, et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: A pilot study. J Psychiatr Res. 2007;41:338–43.
    1. Genazzani AR, Gambacciani M, Simoncini T, Schneider HP. Hormone replacement therapy in climacteric and aging brain. International Menopause Society Expert Workshop, 15-18 March 2003, Pisa, Italy. Climacteric. 2003;6:188–203.
    1. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550–4.
    1. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930–3.
    1. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: A preliminary report. Am J Obstet Gynecol. 2000;183:414–20.
    1. Schneider MA, Brotherton PL, Hailes J. The effect of exogenous oestrogens on depression in menopausal women. Med J Aust. 1977;2:162–3.
    1. Schneider HP. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. Int J Fertil Womens Med. 1997;42(Suppl 2):365–75.
    1. Zweifel JE, O’Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189–212.
    1. Amsterdam J, Garcia-España F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55:11–7.
    1. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002;287:591–7.
    1. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529–34.
    1. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas. 2005;50:91–7.
    1. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology. 2005;30:309–15.
    1. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839–54.
    1. Heinrich AB, Wolf OT. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: A questionnaire study. Neuropsychobiology. 2005;52:17–23.
    1. Robinson GE, Stirtzinger R. Psychoeducational programs and support groups at transition to menopause. In: Steward DE, Robinson GE, editors. A Clinician's Guide to Menopause. Washington, DC: Health Press International; 1997. pp. 165–80.
    1. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351–8.
    1. La Rue A. New York: Plenum Press; 1992. Aging and Neuropsychological Assessment.
    1. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345–57.
    1. Duka T, Tasker R, McGowan JF. The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females. Psychopharmacology (Berl) 2000;149:129–39.
    1. Caldwell BM, Watson RI. An evaluation of psychologic effects of sex hormone administration in aged women. I. Results of therapy after six months. J Gerontol. 1952;7:228–44.
    1. Hackman BW, Galbraith D. Replacement therapy and piperazine oestrone sulphate (’Harmogen’) and its effect on memory. Curr Med Res Opin. 1976;4:303–6.
    1. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA. 1998;279:688–95.
    1. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000;283:1007–15.
    1. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA. 2003;289:2651–62.
    1. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2959–68.
    1. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med. 2002;11:367–77.
    1. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, et al. Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002;77:660–5.
    1. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: A double-blind, cross-over study. Psychoneuroendocrinology. 1985;10:325–35.
    1. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril. 2003;79:1341–52.
    1. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682–8.
    1. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol. 2005;105:944–52.
    1. Soares CN, Joffe H, Steiner M. Menopause and mood. Clin Obstet Gynecol. 2004;47:576–91.
    1. Murphy PJ, Campbell SS. Sex hormones, sleep, and core body temperature in older postmenopausal women. Sleep. 2007;30:1788–94.
    1. Krystal AD. Depression and insomnia in women. Clin Cornerstone. 2004;6(Suppl 1B):S19–28.
    1. Miller EH. Women and insomnia. Clin Cornerstone. 2004;6(Suppl 1B):S8–18.
    1. Shin K, Shapiro C. Menopause, sex hormones, and sleep. Bipolar Disord. 2003;5:106–9.
    1. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;28(Suppl 2):17–54.
    1. Marsh WK, Templeton A, Ketter TA, Rasgon NL. Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: Preliminary report. J Psychiatr Res. 2008;42:247–51.
    1. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. 2004;6:2–13.
    1. Claudia P, Andrea C, Chiara C, Stefano L, Giuseppe M, Vincenzo DL, et al. Panic disorder in menopause: A case control study. Maturitas. 2004;48:147–54.
    1. Smoller JW, Pollack MH, Wassertheil-Smoller S, Barton B, Hendrix SL, Jackson RD, et al. Prevalence and correlates of panic attacks in postmenopausal women: Results from an ancillary study to the Women's Health Initiative. Arch Intern Med. 2003;163:2041–50.
    1. Lochner C, Hemmings SM, Kinnear CJ, Moolman-Smook JC, Corfield VA, Knowles JA. Corrigendum to gender in obsessive-compulsive disorder: Clinical and genetic findings. Eur Neuropsychopharmacol. 2004;14:437–45.
    1. Bluming AZ. Hormone replacement therapy: Benefits and risks for the general postmenopausal female population and for women with a history of previously treated breast cancer. Semin Oncol. 1993;20:662–74.
    1. Burkman RT, Collins JA, Greene RA. Current perspectives on benefits and risks of hormone replacement therapy. Am J Obstet Gynecol. 2001;185:S13–23.
    1. Gorsky RD, Koplan JP, Peterson HB, Thacker SB. Relative risks and benefits of long-term estrogen replacement therapy: A decision analysis. Obstet Gynecol. 1994;83:161–6.
    1. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140–7.
    1. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276–85.
    1. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350:1047–59.
    1. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92:328–32.
    1. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol. 1995;85:304–13.
    1. Syamala TS, Sivakami M. New Delhi: Benett Coleman and Co; 2007. India Women Reaching Menopause at 30: Study, in Times of India.
    1. Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for application in epidemiologic investigations. Am J Epidemiol. 1994;140:1091–5.
    1. Chowta NK, Sebastian J, Chowta MN. Comparative study of menopausal symptoms in post menopausal and perimenopausal women. J Clin Diagn Res. 2008;2:959–62.
    1. Taylor DL, Fonseka P. Symptom experience of Filipino American midlife women. Menopause. 1999;6:105–14.
    1. Goonaratna C, Fonseka P, Wijeywardene K. Perimenopausal symptoms in Sri Lankan women. Ceylon Med J. 1999;44:63–9.
    1. Lagos X, Navarro N, Illanes E, Bustos L. Prevalence of biological and psychological symptoms in perimenopausal women from different socioeconomic levels in the city of Temuco. Rev Med Chil. 1998;126:1189–94.
    1. Schindler BA. The psychiatric disorders of midlife. Med Clin North Am. 1987;71:71–85.
    1. Singh M, Singh G. A comparison of mental health status during menopause and post-menopause middle-aged working women. Internet J World Health Soc Politics. 2007;4:61–9.
    1. Sagsöz N, Oguztürk O, Bayram M, Kamaci M. Anxiety and depression before and after the menopause. Arch Gynecol Obstet. 2001;264:199–202.
    1. Prakash IJ, Murthy VN. Psychiatric morbidity and the menopause. Indian J Psychiatry. 1981;23:242–6.
    1. Indira SN, Murthy VN. Nature of psychiatric disturbances in menopausal women. Indian J Clin Psychol. 1980;7:7.
    1. Nagar S, Dave P. Perception of women towards physiological problems faced at menopause. Anthropologist. 2005;7:173–5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe